Multiple Sclerosis Medication Use

    Basic Details
    Date Posted
    Wednesday, January 8, 2014
    Status
    Complete
    Medical Product
    fingolimod HCL
    glatiramer acetate
    interferon beta-1A
    interferon beta-1A/albumin
    interferon beta-1B
    mitoxantrone HCL
    natalizumab
    Description

    Summary table assessment of the use of seven Multiple Sclerosis drug products: Fingolimod HCL, Glatiramer Acetate, Mitoxantrone HCL, Interferon Beta-1A, Interferon Beta-1A/Albumin, Interferon Beta-IB, and Natalizumab. Results were generated using the Mini-Sentinel Distributed Query Tool and the Dispensing Summary Table. Summary tables are precompiled stratified counts. Queries were executed in February 2013. This report includes data from 17 Data Partners.

    If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    CDER
    Time Period
    2000 - 2012
    Study Type
    Summary Table
    Assessment Type
    Exploratory Analyses
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)